Schering AG to Market Campath® in South East Asia
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 33 (Table of Contents)
Published: 3 Feb-2003
DOI: 10.3833/pdr.v2003.i33.946 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Schering AG has acquired exclusive rights to develop, sell and distribute Ilex Oncology’s humanized monoclonal antibody Campath (alemtuzumab) in Japan, China and the Asian Pacific Basin...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS